SCHEMBL20733374

SCHEMBL20733374

CCOc1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.66
▸ ALDH1A1 P00352 5/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ HTT P42858 2/20 0.66
▸ CA12 O43570 1/20 0.61
▸ CA1 P00915 1/20 0.61
▸ CA2 P00918 1/20 0.61
▸ CA7 P43166 1/20 0.61
▸ CA9 Q16790 1/20 0.61
▸ POLB P06746 1/20 0.59
▸ NQO1 P15559 1/20 0.54
▸ RECQL P46063 1/20 0.53
▸ CNR2 P34972 1/20 0.52
▸ GAA P10253 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20733373 0.85 CA12 (0.58) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL19001352 0.85 CA12 (0.64) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL22104936 0.84 CA12 (0.56) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL28109018 0.83 HTT (0.73) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL7629089 0.83 LMNA (0.63) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL28109405 0.81 CA12 (0.58) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL20387948 0.81 PSEN1 (0.56) LMNAALDH1A1SMN1; SMN2HTTCNR2
SCHEMBL931421 0.79 CA12 (0.70) LMNAALDH1A1SMN1; SMN2CA12CA1
SCHEMBL3269887 0.79 CA12 (0.63) LMNAALDH1A1SMN1; SMN2HTTCA12
SCHEMBL3372297 0.79 ALDH1A1 (0.58) LMNAALDH1A1SMN1; SMN2HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200190034-A1 Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-06-18 — — US disclosed
WO-2019032563-A1 INHIBITORS OF BASE EXCISION REPAIR ACTIVITY AND THERAPEUTIC METHODS BASED THEREON THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2019-02-14 — — WO disclosed
CN-106008288-A Benzsulfamide compound and application thereof 西北农林科技大学 2016-10-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190034-A1 Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon OGG1, UNG, MPG LMNA 2093/4885ALDH1A1 1682/4885SMN1; SMN2 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback